EXHIBIT 99.1

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

CLEARWATER, FL — August 6, 2026 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion^® and the AYON Body Contouring System™ (AYON), today reported financial results for its second quarter ended June 30, 2026.

Recent Financial and Operating Highlights:

“We are excited by the increasing demand for AYON throughout the U.S. market, which we believe reflects the successful execution of our commercial strategy. As a result, we reported 28% growth for the Surgical Aesthetics segment and expect AYON to continue to drive growth through the second half of the year,” said Charlie Goodwin, President and Chief Executive Officer. “U.S. Surgeons continue to recognize the value of an all-in-one body contouring platform that brings together the technologies they rely on every day. With the recent FDA clearance of AYON's power liposuction capability, we are executing a measured rollout with key surgeons ahead of a initial commercial shipments in June. Alongside the expanding body of clinical evidence supporting Renuvion, these milestones reinforce our confidence in the long-term growth opportunity for our business. ”

1

---

The following tables present revenue by reportable segment and geography:

Second Quarter 2026 Results:

Total revenue for the three months ended June 30, 2026, increased 22% to $13.9 million, compared with $11.4 million in the prior year period. Surgical Aesthetics segment sales increased 28%, or $2.7 million, to approximately $12.4 million for the three months ended June 30, 2026, when compared with $9.7 million for the three months ended June 30, 2025. The Surgical Aesthetics sales increase was driven by sales of AYON, which commenced with the commercial launch in the third quarter of 2025, increased sales of generators internationally and increased volume of single-use handpieces domestically. These increases were partially offset by decreases in domestic sales of standalone generators. OEM segment sales decreased 12%, or $0.2 million, to approximately $1.5 million for the three months ended June 30, 2026 when compared with $1.7 million for the three months ended June 30, 2025. The decrease in OEM sales was due to a decrease in sales volume to existing customers. With the increased focus on Surgical Aesthetics, the Company expects that OEM segment revenue will decrease for the year and that this trend will continue over time.

Gross profit for the three months ended June 30, 2026, increased 25% to $8.9 million, compared with $7.1 million for the same period in the prior year. Gross margin for the three months ended June 30, 2026, was 63.9%, compared to 62.3% for the same period in 2025. The increase in gross margin for the three months ended June 30, 2026 from the prior year period is primarily attributable to mix between the Company’s segments with Surgical Aesthetics comprising a higher percentage of total sales and product mix within the OEM segment. This was partially offset by tariffs that began effecting the Company in the second half of 2025.  

2

---

 

Operating expenses increased to $10.7 million for the three month period ended June 30, 2026, compared with $9.7 million for the same period last year. The increase in operating expenses was driven by a $1.0 million increase selling, general and administrative expenses and a $0.3 million increase in salaries and related costs, partially offset by a $0.3 million decrease in professional services.

Other expense, net was relatively flat at $1.1 million for each of the three months ended June 30, 2026 and 2025.

Net loss attributable to stockholders was $3.2 million, or $0.07 per share, for the three months ended June 30, 2026, compared with $3.8 million, or $0.09 per share, in the prior year period.

Adjusted EBITDA loss for the three months ended periods ended June 30, 2026 was $0.7 million as compared with an Adjusted EBITDA loss of $2.0 million for the three months ended June 30, 2025.

For the three months ended June 30, 2026, net cash used in operating activities was $3.5 million, compared with $1.2 million used in the three months ended June 30, 2025. The increase was primarily due to changes in working capital, partially offset by a reduction in operating loss.

As of June 30, 2026, the Company had cash and cash equivalents of $27.6 million. Management believes based on its projections, including the uptake of the AYON platform, working capital management and its strict cost controls, the Company will yield cash through 2027.

Financial Guidance for Full Year 2026:

The Company reaffirmed its financial guidance targets for the year ending December 31, 2026:

3

---

 

Conference Call Details:

Management will host a conference call at 4:30 p.m. Eastern Time today, August 6th to discuss the results of the second quarter ended June 30, 2026, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 53282. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the Investor Relations section of the Company’s website and accessible directly via the following link:

https://viavid.webcasts.com/starthere.jsp?ei=1766208&tp_key=132ba2dca7

An archive of the webcast will be accessible approximately one hour after the live event ends on the Investor Relations section of the Company’s website.

Investor Relations Contact:

Jeremy Feffer, Managing Director, LifeSci Advisors

OP: 212-915-2568

jfeffer@lifesciadvisors.com

About AYON Body Contouring System™:

AYON is a groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates advanced fat removal technologies, Renuvion’s tissue contraction and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. With advanced features like LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, AYON sets a new standard in surgical care, streamlining procedures and maximizing patient outcomes. Backed by Apyx Medical’s expertise and evidence-based design, AYON delivers consistent, reliable performance and an unmatched return on investment. As the first of its kind, AYON is revolutionizing body contouring and shaping the future of aesthetic surgery.

About Apyx Medical Corporation:

Cautionary Statement on Forward-Looking Statements:

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.

Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

4

---

 

APYX MEDICAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited) (In thousands, except per share data)

5

---

 

APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)

6

---

 

APYX MEDICAL CORPORATION
RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA
(Unaudited)

Use of Non-GAAP Financial Measure

The Company has presented the following non-GAAP financial measure in this press release: adjusted EBITDA. The Company defines adjusted EBITDA as its reported net income (loss) attributable to stockholders (GAAP) plus income tax expense (benefit), interest, depreciation and amortization, stock-based compensation expense and other significant non-recurring items.

We present the following non-GAAP measure because we believe such measure is a useful indicator of our operating performance. Our management uses this non-GAAP measure principally as a measure of our operating performance and believes that this measure is useful to investors because it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We also believe that this measure is useful to our management and investors as a measure of comparative operating performance from period to period. The non-GAAP financial measure presented in this release should not be considered as a substitute for, or preferable to, the measures of financial performance prepared in accordance with GAAP.